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ABSTRACT 
Intraperitoneal (IP) chemotherapy is an effective way of treating peritoneal carcinomatosis of 
colorectal origin after complete cytoreduction. Although IP therapy has been already performed for 
many years, no standardized treatment design has been developed in terms of schedule, residence 
time, drug or carrier solution. Because of the fast clearance of the conventional intravenous (IV) drug 
delivery systems used for IP therapy, a lot of research is performed to optimize IP drug delivery and 
extend the residence time of the cytotoxic agent in the peritoneal cavity. This paper reviews the 
recent advances made in drug delivery systems for IP chemotherapy, discussing the use of 
microparticles, nanoparticles, liposomes, micelles, implants and injectable depots for IP delivery.  
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INTRODUCTION 
Colorectal cancer is the third most common cancer and ranks as the fourth most common cancer-
related mortality [1]. A major component of treatment failure is cancer dissemination within the 
abdominal and pelvic spaces as a local recurrence of the primary cancer or as peritoneal 
carcinomatosis (PC). It is estimated that about 40 % of the patients with colorectal cancer will 
develop PC during the evolution of the disease [2] as a result of the growth of the primary tumor 
through the serosal lining of the bowel lumen, thereby allowing the exfoliation and shedding of 
malignant cells intraperitoneally. Manipulation during the surgical procedure may also release tumor 
cells within the peritoneal cavity [2]. 
PC from colorectal cancer was traditionally regarded as a terminal condition. The terminal nature of 
this disease has been demonstrated in a large clinical trial, the French multicentric EVOCAPE-1 trial, 
which prospectively followed up 370 patients with PC of different primary cancers from diagnosis till 
death. The mean survival of 118 patients with PC from colorectal cancer was 6.0 months [3]. 
For over two decades, adjuvant intravenous (IV) therapy with 5-fluorouracil (5-FU) has improved the 
therapeutic outcome after cytoreduction [4]. After the introduction of oxaliplatin in combination 
with 5-FU or leucovorin, the effectiveness of systemic treatment of PC was improved [5,6]. A 
combination of these agents in randomized clinical trials in patients with metastatic colorectal cancer 
increased the median survival up to 20 months [7,8]. This combination IV therapy is the current 
standard of care for adjuvant therapy of resected colon cancer. 
Since the 1980s, different treatment options for patients with isolated PC were proposed based on 
the hypothesis that PC is a local-regional disease which would benefit from a local therapeutic 
approach [9]. The rationale of using local intraperitoneal (IP) therapy for the treatment of PC is based 
on the pharmacokinetic advantages, such as high local concentration with a longer half-life of the 
drug in the peritoneal cavity, which improves the interaction of the cytotoxic agents with the cancer 
cells. 
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Over the last decades, some researchers focused on improving the drug delivery systems for IP 
therapy. Research towards IP drug delivery has focused on means to obtain higher drug 
concentrations at the site of the disease in combination with a reduction of the toxicity to healthy 
tissue. This paper reviews the different strategies that have been developed to control drug release 
in combination with a low systemic toxicity and an extended residence time of the cytotoxic drug in 
the peritoneal cavity [10]. Micro- and nanoparticles, liposomes, micelles, implants and injectable 
depots are discussed.  
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INTRAPERITONEAL CHEMOTHERAPY 
The current treatment protocols for peritoneal carcinomatosis are based on a combination of 
cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy. 
The first step is to eliminate all macroscopic disease by CRS since the size of the residual tumor 
nodules is the major prognostic indicator for the outcome of the disease. CRS is considered complete 
when no visible evidence of cancer remains (CC-0), or when only small residual nodules with a size 
less than 2.5 mm remain (CC-1), as this small size ensures full drug penetration into the tumor during 
subsequent intraperitoneal chemotherapy. CRS with residual tumors with a diameter > 2.5 mm (CC-2 
and CC-3) is considered to be incomplete and these patients have a low survival rate [11,12].  
A second essential part of the current management of PC is the perioperative intraperitoneal 
chemotherapy which targets the residual microscopic disease. IP treatment of patients with PC was 
first reported by Spratt et al., who used triethylenethiophosphoramide in a patient with 
pseudomyxoma peritonei [9] and by Speyer & Myers, who administered 5-FU and methotextrate 
intraperitoneally under normothermic conditions to 16 patients with PC [13]. In 1988, Koga et al. 
reported intraperitoneal chemotherapy in 23 patients with PC from gastric cancer origin [14]. 
The adjuvant perioperative intraperitoneal chemotherapy can be applied directly after CRS under 
normothermic or hyperthermic conditions (i.e. (hyperthermic) intraperitoneal chemotherapy or 
(H)IPEC) as a part of the surgical procedure, or can be started the first postoperative day and 
continued for several (usually five) days (i.e. early postoperative intraperitoneal chemotherapy or 
EPIC). No randomized trials have been published comparing the survival outcomes between EPIC and 
HIPEC [15]. EPIC has been associated with a higher risk of complications after CRS, possibly due to the 
prolonged contact between the chemotherapeuticum and damaged tissues at the operated surfaces 
[16]. Other disadvantages of EPIC are an uneven distribution of the chemotherapeutic fluid in the 
abdomen and causing less comfort for the patients (e.g. nausea and impaired mobility) linked to the 
chemotherapeutic fluid present in the abdomen [17]. As the main drawback of HIPEC is the necessity 
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to perform this technique in the operating room, requiring specialized equipment and an 
experienced perfusionist, HIPEC is the preferred technique. When performing the open HIPEC 
technique, the abdomen is covered with a plastic sheet, aerosolized droplets for the IP heated 
chemotherapy are aspirated and the surgeon who is manipulating the viscera is wearing special 
sterile gloves; each of these a precaution to minimize the risk of exposure of the operating room 
personnel to the chemotherapeuticum  [18]. In most cases HIPEC is performed under hyperthermic 
conditions (41-42 °C) as hyperthermia is claimed to enhance the effect of different cytotoxic agents 
(e.g. mitocyn C, doxorubicin, cisplatin and oxaliplatin) [19]. However, some studies suggest that there 
is no synergistic effect between the cytotoxic agent and hyperthermia, and no differences were 
observed when performing IP at normothermic or hyperthermic conditions [15,20]. 
Promising results when combining CRS and perioperative chemotherapy were reported in several 
studies. HIPEC with mitomycin C followed by systemic chemotherapy resulted in a 45 % 5-year 
survival in colorectal patients receiving complete cytoreduction [21]. In a second study the 5-year 
survival among 1290 patients with PC from different primary origins receiving CRS and perioperative 
chemotherapy was 37 % [12].  
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DRUG SELECTION FOR IP THERAPY 
Although IP therapy is already conducted for many years, no standard treatment in terms of 
schedule, residence time, drug, or carrier solution has been established. In the case of IP therapy, the 
cytotoxic agent must be able to penetrate the peritoneal surface and the tumor nodules effectively, 
in combination with its ability to eradicate microscopic residual disease within the peritoneal fluid. 
During IP therapy, drug delivery to peritoneal tumors is twofold. The primary route is drug diffusion 
through the tumor interstitium, while the second route is the recirculation of the drug absorbed from 
the peritoneal cavity. However, it is evident that the latter route is of minor importance as efficient 
and safe IP therapy requires systemic drug levels as low as possible in order to minimize systemic 
side effects caused by the cytotoxic agent. 
One of the major challenges of IP therapy is to maintain a high local drug concentration within the 
peritoneal cavity to provide a sufficient concentration gradient as driving force for drug diffusion into 
the tumor. The residence time of small molecular weight drugs in the peritoneal cavity may not be 
sufficient because they are quickly absorbed through the peritoneal capillaries into the systemic 
circulation [22]. Therefore, the drug delivery system used for IP therapy is an important factor to 
deliver drugs efficiently to the target tissue. In addition, different parameters must be considered to 
select the ideal chemotherapeutic agent for IP therapy and to maximize its efficacy: cavity-to-plasma 
AUC ratio, systemic absorption, depth of tumor penetration, intrinsic activity of the agent against the 
primary tumor type. In general, water insoluble molecules with a high molecular weight and a high 
cavity-to-plasma AUC ratio remain longer in the peritoneal cavity and are thus preferred for IP 
treatment (Table I) [23,24]. One important consideration is that a high cavity-to-plasma AUC ratio 
does not automatically confer a higher efficacy, since penetration of the chemotherapeutic agent 
into the tumor might be limited. 
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Tabel I: Water solubility, the partition coefficient (log P) and peritoneal to plasma drug area under 
the curve (AUC) ratio of intraperitoneal chemotherapeutic agents 
Chemotherapeutic agent Molecular weight Water solubility Log P 
Peritoneal to 
plasma AUC ratio 
Cisplatin 300 Good -2.19 12 
Carboplatin 371 Good 1.06 10-18 
Oxaliplatin 397 Good 1.73 16 
Paclitaxel 854 Poor 3.54 1000 
Docetaxel 862 Poor 2.92 181 
5-Fluorouracil 130 Sparingly -0.89 367 
Doxorubicin 544 Poor 1.27 474 
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DRUG DELIVERY SYSTEMS FOR IP THERAPY 
Inadequate drug delivery to solid tumors is a major cause of IP treatment failure. Today there are no 
chemotherapeutic formulations specifically approved for IP therapy, and current  IP chemotherapy in 
patients relies on the off-label use of products developed for IV applications. These formulations 
designed for IV therapy often suffer from a rapid clearance from the peritoneal cavity, fast 
absorption through the lymphatics, no tumor selectivity and local and systemic toxicity caused by the 
high blood concentrations after systemic absorption. These issues, which reduce the efficacy of IP 
therapy, dramatically limit the use of conventional IV chemotherapeutic formulations for IP use [25]. 
As a result, a number of drug delivery strategies (which are reviewed in the remainder of this paper) 
have been investigated to extend the residence time of the chemotherapeutic agent and to optimize 
IP therapy (Table 2). 
 
Microspheres 
Microspheres (>1 µm) can be designed to release the drug gradually over time using a wide variety of 
biodegradable and biocompatible polymeric substances. The size of the microspheres is the most 
important factor that influences residence time in the peritoneum, since microspheres smaller than 8 
µm may disappear from the peritoneal cavity through the lymphatic capillaries [26].  
Microspheres for IP drug delivery are often based on biodegradable aliphatic polyesters of hydroxyl 
acids such as poly(lactic-co-glycolic)acid (PLGA) and related polymers. PLGA was for example used to 
incorporate cisplatin (cis-dichlorodiammmine-platinum(II)) in microspheres. Cisplatin is a hydrophilic 
molecule which is, in solution, rapidly absorbed from the peritoneal cavity by the capillaries and 
transferred to the systemic circulation. Therefore biodegradable anti-cancer drug-loaded 
microspheres were developed which showed a long retention and sustained release of the drug. 
Cisplatin was released from the PLGA matrix by diffusion until 14 days after IP administration. During 
this period the particles were retained in the abdominal cavity for a long period and gradually 
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absorbed, which reduced the systemic side effects [27]. Another drug delivery system using PLGA is 
paclitaxel-loaded microparticles [28]. This system consists of two types of paclitaxel-loaded 
microparticles with different drug release rates obtained by the lactide/glycolide (L/G) ratio. First, a 
burst release was observed (L/G 50:50), followed by a sustained drug release (L/G 75:25).  As 
paclitaxel is a promising molecule for IP treatment, paclitaxel-containing microsphere formulations 
based on other polymers were also developed. Paclimer® was made by incorporating paclitaxel in a 
biodegradable poly-phosphoester polymer matrix, to form microspheres with a mean particle size of 
53 µm. These microparticles resulted both in vitro and in vivo (after IP administration in a phase I 
study) in a sustained release of paclitaxel over a period of 8 weeks [29]. The triblock poly (ε-
caprolactone)-poly(ethyleneglycol)-poly (ε-caprolactone) (PCL-PEG-PCL) copolymer was synthesized 
to prepare camptothecin-loaded microspheres. These microspheres were developed to protect 
camptothecin from hydrolysis, thus enhancing its treatment efficacy towards colorectal peritoneal 
carcinomatosis [30]. 
 
Nanoparticles 
Although microspheres have a longer retention time in the peritoneal cavity, they can also induce 
inflammatory reactions and peritoneal adhesions [31]. Because of these issues the benefit-to-risk 
ratio should be taken into account when deciding between microparticles and nanoparticles. Kohane 
et al. showed that nanoparticles and microparticles formulated with lower molecular weight 
polymers had a much lower incidence of peritoneal adhesions and were safer to use [32]. Another 
advantage of nanoparticles is that they can bypass drug efflux pumps, thus evading multi-drug 
resistance and achieving significantly higher drug accumulation in the cells compared to IP therapy 
with the unformulated free drugs [33] [34]. Although conventional nanoparticles are rapidly cleared 
from the abdominal cavity due to their size, nanoparticles which respond to a wide array of stimuli 
such as pH, temperature, light and ultrasound, are being investigated. For IP therapy, paclitaxel-
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loaded pH responsive nanoparticles were developed which were designed to deliver paclitaxel 
intracellularly after endocytosis. In this formulation paclitaxel is encapsulated in an acrylate-based 
polymer with a pH-responsive 2,4,6-trimethoxybenzaldehyde protective group. These nanoparticles 
react to an endosomal pH (pH ≤ 5) and increase in volume to release their drug load. When these 
nanoparticles are IP injected in a mice tumor model, they remain in the peritoneal cavity for 7 days 
[35]. 
 
Liposomes 
Liposomes have been widely studied as potential carriers for hydrophilic and hydrophobic drugs and 
diagnostic agents. Due to their small size (100 – 1000 nm), liposomes have a fast clearance from the 
abdominal cavity. As such it is important to change some of the liposomes characteristics such as 
lipid composition, surface properties and charge, in order to increase their retention time in the 
abdominal cavity. Hirano et al (1985) described that the charge of the liposomes is a predictive factor 
for the retention time [22]. When the liposomes have a negative charge, they were rapidly absorbed 
from the peritoneal cavity, while positively charged liposomes had a slower absorption rate. This 
might be attributed to electrostatic interaction between the positively charged liposomes and the 
negative surface of the peritoneal mesothelium, in combination with a low uptake of positive 
liposomes by peritoneal macrophages [36]. Changing the type of phospholipid (the main building 
block of liposomes) has no effect on retention time in the abdominal cavity [37], whereas the 
incorporation of polyethylenglycol (PEG) in the phospolipid membrane showed a 30 % higher 
peritoneal retention by the avoidance of the macrophages present in the peritoneal cavity,  
compared to the same non-pegylated liposomes [36].  
 
Micelles 
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Taxol®, a micellar paclitaxel formulation using Cremophor®EL (i.e. a polyethoxylated castor oil 
surfactant) is used for IP treatment of ovarian cancer. Taxol® showed a longer residence time in the 
abdominal cavity compared to free unformulated paclitaxel (40.7 ± 13.8 h vs 7.3 ± 2.8 h), which 
indicated that encapsulation is an effective way to extend the residence time of a drug in the 
abdominal cavity [38]. But due to the surfactant (Cremophor®EL) included in the formulation, Taxol® 
is not well tolerated as hypersensitivity reactions and neurotoxicity are reported [39]. IP 
chemotherapy using a nanocrystalline paclitaxel formulation stabilized by Pluronic F127® (i.e. 
polyethylene oxide-polypropylene oxide (PEO-PPO) block copolymer) showed a faster recovery of the 
animals compared to treatment with Taxol®, while the cytotoxicity and antitumor efficacy was similar 
[40]. Several studies showed that the carrier plays an important factor in the distribution and 
clearance of the drugs after IP administration [38] [41]. 4.2 % Cremophor®EL and 1.5 % polysorbate-
80 were used to solubilize paclitaxel and docetaxel, respectively. In a rat model, the absorption rate 
of these taxanes was influenced by the solubilizer in the system. While the AUCip of paclitaxel 
doubled in comparison to docetaxel, when conventional vehicles were used, dissolution of docetaxel 
in 4.2 % Cremophor EL or 7.5 % Polysorbate-80, increased its retention time and yielded similar AUCip 
values compared to paclitaxel [42]. 
 
Implants and injectable depots 
Implantable and injectable depots have been investigated for localized and sustained delivery of 
anticancer agents [43]. Those systems may be the most promising approach for the IP treatment of 
PC. The rationale of using hydrogels for IP therapy is dual as a hydrogel will retain the drugs within 
the peritoneum and will also protect against peritoneal adhesions [44]. A major drawback for 
hydrogels is achieving homogeneous distribution of the drug in the peritoneal cavity. Also the 
viscosity of the injectable hydrogels can cause problems. Low viscous sytems may fail to provide a 
delayed drug release profile, while highly viscous systems may be difficult to administer [43]. 
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Because of these problems thermosensitive hydrogels are developed. These gels are free-flowing at 
room temperature and form a non-flowing gel at body temperature, serving as an in situ drug depot. 
Therefore the formulation can be easily mixed with the drugs and injected by a syringe as a fluid, 
while forming a viscous deposition at the target location [45]. This gelation behavior is primarily due 
to the formation of self-associated micelles via hydrophobic interactions. Above the lower critical 
solution temperature, these micelles are closely packed together resulting in micellar aggregation 
and a change of rheological properties  [46]. Gong et al. reported that a hydrogel system based on a 
biodegradable poly(ethylene glycol)-poly(ε-caprolactone)-poly(ethylene glycol) (PEG-PCL-PEG, PECE) 
triblock copolymer, could be used as a delivery vector of chemotherapeutic drugs for IP infusion 
chemotherapy. The system was loaded with 5-FU [47] and doxorubicin [48]. When the system was 
infused intraperitoneally in mice, the formed gel phase guaranteed a delayed drug release up to 48 
hours after injection. 
Implantable systems were developed for IP treatment of ovarian cancer. This implant is composed of 
paclitaxel-loaded poly-D,L-lactide and poly(lactide)-block-poly(ethylene glycol) (PLA-b-PEG) particles 
dispersed throughout a chitosan egg-phophatidylcholine matrix. This formulation provided a 
sustained and localized release of 1 % PTX per day in mice over a period of 3 months [49,50]. The 
implants have a higher efficacy and are less toxic and more biocompatible than Taxol®. Although the 
implantable systems have promising results, the biggest issue for using those systems is the need for 
surgical expertise to implant the system. 
 
Carrier solutions 
A simple approach to improve IP administration of chemotherapeutic agents using conventional 
formulations is varying the medium in which the drug is dissolved or suspended. The volume of the 
fluid in which the chemotherapeutic agent is dissolved plays an important role towards drug 
distribution in the peritoneal cavity. The ideal carrier solution for IP chemotherapy should expose all 
cancerous surfaces or residual tumor cells to high levels of cytotoxic agents for as long as possible 
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and ensure a uniform distribution of the drug in the abdominal cavity. Small volumes of fluid do not 
flow freely in the peritoneum, even with multiple position changes of the patients [51], while large 
volumes (>2L/m2 body surface area) which cause moderate abdominal distention result in more 
uniform intraperitoneal drug distribution. Hence maintaining a high volume of the intraperitoneal 
liquid would improve the effectiveness of the treatment as the choice of the solution, in which the 
drug is administered, plays an important role in the distribution of the drugs [52] [53]. Current 
techniques for IP chemotherapy administration mainly use isotonic electrolyte solutions (e.g. 5 % 
glucose, 0.9 % sodium chloride). However isotonic salt and dextrose solutions are rapidly absorbed 
due to their low molecular weight [53,54] [52] which decreases the distribution of the drug in the 
peritoneal cavity. Hypotonic solutions showed promising in vitro results as they increased 
cytotoxicity and accumulation of cisplatin in tumor cells [55]. However, the clinical results were 
negative as bleeding and thrombocytopenia occurred, while no pharmacokinetic advantages were 
observed [56] [57]. When hypertonic solutions were used a prolonged retention time of the 
intraperitoneal volume was achieved, but their main disadvantage is the dilution of the 
intraperitoneal drug due to fluid shift to the peritoneal cavity [52]. 4 % icodextrin, a colloid osmotic 
agent of the α-1,4 linked glucose polymer, has been successfully used to prolong retention of 
intraperitoneal chemotherapy, the solution can remain 3 to 4 days in the peritoneum [58]. Another 
iso-osmolar solution, with a potentially long intraperitoneal dwell time, is 6 % hydroxyethyl starch 
(hetastarch) which has been successfully used to prolong intraperitoneal retention of gemcitabine 
and paclitaxel in animal studies [52,59]. Also the use of HAES-steri, a starch-based carrier solution, 
reduced the clearance of the chemotherapeutic solutions from the peritoneal cavity compared to 
physiological saline solution [60].   
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Table 2: Advantages and disadvantages of the drug delivery systems investigated for IP therapy 
Drug delivery system Advantages Disadvantages 
Microspheres 
Prolonged retention time Limited tumor penetration 
Risk of peritoneal adhesions 
Nanoparticles 
Due to small size passive targeting 
Avoiding MDR 
Lower incidence of peritoneal 
adhesions 
Rapid clearance out of the 
abdominal cavity 
Liposomes 
Similar to nanoparticles 
Active targeting by varying parameters 
Similar to nanoparticles 
Micelles Prolonged retention time Increasing systemic toxicity 
Injectable systems 
Prolonged retention time 
Localized and sustained drug delivery 
Lower systemic toxicity 
Prevention against peritoneal adhesion 
Viscosity issues 
Implantable systems 
Similar to injectable systems Invasive 
Surgical expertise 
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CONCLUSION 
Cytoreductive surgery followed by intraoperative intraperitoneal chemotherapy has proven to be a 
very effective treatment for patients with peritoneal carcinomatosis of colorectal origin.  
For the moment there are no chemotherapeutic agents specifically designed or approved for IP 
therapy. This review indicates the important role of the different drug delivering system to deliver 
the cytotoxic agents more adequately. The requirements for a good drug delivery systems for IP 
therapy are that high loco-regional drug concentrations are maintained for a longer period in 
combination with a lower non-specific toxicity. If these drug delivery systems can be combined with 
high molecular weight drugs with a high peritoneal cavity-to-plasma AUC ratio, this could result in a 
more effective way of treating PC.  
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